Recherche

Bull, Caroline J.; Bell, Joshua A.; Murphy, Neil; Sanderson, Eleanor; Davey Smith, George; Timpson, Nicholas J.; Banbury, Barbara L.; Albanes, Demetrius; Berndt, Sonja I.; Bézieau, Stéphane; Bishop, D. Timothy; Brenner, Hermann; Buchanan, Daniel D.; Burnett-Hartman, Andrea; Casey, Graham; Castellví-Bel, Sergi; Chan, Andrew T.; Chang-Claude, Jenny; Cross, Amanda J.; de la Chapelle, Albert; Figueiredo, Jane C.; Gallinger, Steven J.; Gapstur, Susan M.; Giles, Graham G.; Gruber, Stephen B.; Gsur, Andrea; Hampe, Jochen; Hampel, Heather; Harrison, Tabitha A.; Hoffmeister, Michael; Hsu, Li; Huang, Wen-Yi; Huyghe, Jeroen R.; Jenkins, Mark A.; Joshu, Corinne E.; Keku, Temitope O.; Kühn, Tilman; Kweon, Sun-Seog; Le Marchand, Loic; Li, Christopher I.; Li, Li; Lindblom, Annika; Martín, Vicente; May, Anne M.; Milne, Roger L.; Moreno, Victor; Newcomb, Polly A.; Offit, Kenneth; Ogino, Shuji; Phipps, Amanda I.; Platz, Elizabeth A.; Potter, John D.; Qu, Conghui; Quirós, J. Ramón; Rennert, Gad; Riboli, Elio; Sakoda, Lori C.; Schafmayer, Clemens; Schoen, Robert E.; Slattery, Martha L.; Tangen, Catherine M.; Tsilidis, Kostas K.; Ulrich, Cornelia M.; van Duijnhoven, Fränzel J. B.; van Guelpen, Bethany; Visvanathan, Kala; Vodicka, Pavel; Vodickova, Ludmila; Wang, Hansong; White, Emily; Wolk, Alicja; Woods, Michael O.; Wu, Anna H.; Campbell, Peter T.; Zheng, Wei; Peters, Ulrike; Vincent, Emma E.; Gunter, Marc J. — 2020 Additional file 1: Table S1. Genetic variants used to instrument BMI, WHR and metabolites. Table S2. Assesment of instrument strength. Table S3. Colorectal cancer case distributions by study, sex and site. Table S4. LogOR colorectal cancer per SD higher BMI or WHR. Table S5. Beta change in NMR-detected metabolite per SD higher BMI or WHR. Table S6. LogOR colorectal cancer per SD higher BMI or WHR-driven NMR-detected metabolite. Table S7. Risk of overall colorectal cancer per SD higher adipose or metabolite trait, estimated using multivariable Mendelian randomization. Table S8. Posthoc investigations. https://creativecommons.org/licenses/by/4.0/legalcode

Bouras, Emmanouil; Karhunen, Ville; Gill, Dipender; Huang, Jian; Haycock, Philip C.; Gunter, Marc J.; Johansson, Mattias; Brennan, Paul; Key, Tim; Lewis, Sarah J.; Martin, Richard M.; Murphy, Neil; Platz, Elizabeth A.; Travis, Ruth; Yarmolinsky, James; Zuber, Verena; Martin, Paul; Katsoulis, Michail; Freisling, Heinz; Nøst, Therese Haugdahl; Schulze, Matthias B.; Dossus, Laure; Hung, Rayjean J.; Amos, Christopher I.; Ahola-Olli, Ari; Palaniswamy, Saranya; Männikkö, Minna; Auvinen, Juha; Herzig, Karl-Heinz; Keinänen-Kiukaanniemi, Sirkka; Lehtimäki, Terho; Salomaa, Veikko; Raitakari, Olli; Salmi, Marko; Jalkanen, Sirpa; Jarvelin, Marjo-Riitta; Dehghan, Abbas; Tsilidis, Konstantinos K. — 2022 Additional file 2. (Supplemental Tables): Supplementary Table 1. Sources of GX instruments per cytokine & genetic locus of cytokine. Supplementary Table 2. Genetic association estimates that were used in the MR analyses. Supplementary Table 3. Sources of GY instruments per cancer outcome. Supplementary Table 4. Genetic association estimates that were used in the MR analyses. Supplementary Table 5. Summary of the MR results based on the cis-pQTL instrument definition. Supplementary Table 6. Summary of the MR results based on the cis-eQTL instrument definition. Supplementary Table 7. Identification of druggable targets using publicly available repositories. Supplementary Table 8. Summary of epidemiological evidence linking prediagnostic cytokine concentrations to cancer risk. Supplementary Table 9. KeGG pathways in which significant cytokines are involved. Supplementary Table 10. Colocalization analysis. Supplementary Table 11a. Secondary cytokines associated with selected instruments, based on the gwas included in the study. Supplementary Table 11b. Secondary traits associated with selected instruments, based on a phenoscanner search. Supplementary Table 12a. Sensitivity analyses excluding potentially pleiotropic genetic variants. Supplementary Table 12b. Sensitivity analyses accounting for LD among genetic variants. Supplementary Table 13. Replication of the significant associations in the UK Biobank. https://creativecommons.org/licenses/by/4.0/legalcode